ABSTRACT OBJECTIVES This study aimed to examine whether a history of asthma from childhood is associated with left ventricular (LV) mass in adulthood.
L eft ventricular (LV) hypertrophy is recognized as target-organ damage resulting from a chronic increase in pressure and volume overload, with an estimated prevalence of 14.9% for men and 9.1% for women in the general population, and 36% to 41% among hypertensive patients (1, 2) . Left ventricular mass indexed to height 2.7 (LVMI) predicts incident events, progression, and severity stages of heart failure (3). Increased LVMI, a cardiac subclinical measure indicating the extent of LV hypertrophy, is an independent risk factor for death and major cardiovascular (CV) outcomes (4, 5) . Besides traditional CV risk factors, emerging evidence from both experimental and observational studies has linked chronic inflammation to increased LV mass (6, 7) .
Asthma is a chronic inflammatory disorder in which the airway becomes inflamed, narrow, and swollen, thus causing coughing, wheezing, shortness of breath, and chest tightness. The prevalence of asthma has been growing during the past decade with an estimated current prevalence of 8.6% in children (8) and 7.4% in adults (9) . Emerging evidence from epidemiological studies has shown that asthma in adulthood is associated with an increased risk of premature death (10) , coronary heart disease (11), and stroke (12) . However, there is only 1 study analyzing the relationship between adult asthma and heart failure (13) and 1 cross-sectional study assessing the association between asthma and LV hypertrophy in older adults (14) . We saw a need for a prospective study to assess the relationship between a history of asthma from childhood and LV mass. We hypothesized that having a history of asthma from childhood could be related to increased LV mass in later life.
In this study, we performed prospective association analyses between a history of asthma from childhood and LV mass in adulthood in the Bogalusa Heart Study, a large and long ongoing, community-based, biracial, children's cohort study of the natural history of CV risk factors and their impact on vascular and metabolic changes throughout the life span since 1973.
In addition, we were particularly interested in testing the interactions between asthma and all other covariates on LV mass, such as demographics and major cardiovascular disease (CVD) risk factors.
METHODS
STUDY COHORT. The Bogalusa Heart Study is a biracial (65% white and 35% black), community-based, 
RESULTS
With an average of 10.4 AE 7.5 years of follow-up, a total number of 2,473 follow-up measurements of CV subclinical markers were collected in 1,118 individual subjects, and 68.6% of these subjects were followed up 2 to 4 times ( Table 2 ). In the longitudinal cohort (57.4% in female participants and 30.7% in black participants), 9.3% had self-reported asthma, and the mean age was 27.3 AE 9.6 years at baseline. The study variables were compared between the 2 groups (with and without a history of asthma) at both baseline and follow-up. No significant difference was found in sex, race, age, smoking status, SBP, heart rate, hsCRP, and blood pressure medication. However, compared with participants without asthma, subjects with asthma had a longer mean follow-up period hsCRP, heart rate, BMI, and SBP. We found that a history of asthma from childhood appeared to be associated with an increased risk for elevated LVMI among apparently healthy young adults. In addition, we found significant interactions between asthma and SBP on LV mass and LVMI; the associations between asthma and LVMI appeared to be stronger among participants with higher SBP (pre-hypertension and hypertension) than in participants with lower SBP.
The current study prospectively analyzed associations between a history of asthma from childhood and LV mass in adulthood, a prominent indicator of target-organ damage. Our findings are consistent with those of previous studies in which asthma was related to other CV subclinical markers reflecting arterial stiffness in adults, such as carotid artery intimamedia thickness (21) and pulse wave velocity (22) . In addition, previous observational studies also showed that asthmatic subjects had an increased risk of major CVDs and death. In a prospective cohort of 203,595 adults, asthma was associated with a 40% increase in coronary heart disease, a 20% increase in cerebrovascular disease, an 114% increase in heart failure, and a 228% increase in all-cause mortality (13) . Similarly, a 2-fold increased risk of incident coronary heart disease and stroke resulting from asthma was observed in the ARIC (Atherosclerosis Risk In Communities) study (23) .
Our data suggest that asthma is independently associated with increased LVMI, but the mechanisms underlying this epidemiological association remain unclear. Previous evidence emphasized the role of systemic inflammation in the relationship between asthma and CV disorders, given that a higher level of inflammatory markers (e.g., hsCRP, interleukin, leukotrienes, and fibrinogen) in asthmatic subjects could affect myocardial inflammation and remodeling (6), which in turn contribute to LV hypertrophy and later heart failure (7) . Supported by the current study, we observed that a 1-U increase of hsCRP was significantly associated with a 1.40 and 0.40 increase in LV mass and LVMI (model 4 in Table 3 ). However, additional adjustments of hsCRP did not attenuate the positive association between asthma and LVMI.
Similarly, a prospective cohort study showed a 1.59-fold risk of incident CVD events associated with asthma, a risk that was not significantly attenuated by additional control for systemic inflammatory Values are adjusted mean (95% CI). *Mixed regression models were used to adjust for age, sex (male or female), race (black or white), smoking status (current smokers or noncurrent smokers), antihypertensive medication (yes/ no/missing, using "no" as reference), and heart rate (beats/min) as fixed effects, as well as participants' study identity (ID) numbers as random effects. †hsCRP was measured among 1,050 participants (953 and 97 participants without and with a history of asthma, respectively).
Abbreviations as in Table 1 . Values are n (range) or n (%). *Two groups' characteristics were compared using the Student t test or Kruskal-Wallis test for continuous variables and the chisquare test for categorical variables. †Continuous variables were described as either means (SD), if normal distribution was satisfied, or medians (percentile 25th, percentile 75th), if normal distribution was unsatisfied. ‡In the follow-ups, 352 participants had only a 1-time follow-up measurement, and the remaining 825 participants had 2 to 4 repeated follow-up measurements, which added up to a total of 2,639 observations. §hsCRP was measured among 1,050 participants (953 and 97 participants without and with a history of asthma, respectively).
Abbreviations as in Table 1 .
markers (24) . Therefore, except for chronic inflammatory pathophysiological features, the study suggested other that pathogenetic mechanisms could be involved. For example, pulmonary function decline in asthmatic patients could be another potential pathway (25, 26) . Asthmatic airway hyperresponsiveness is a trigger for the compensatory hypertrophic growth of myocardial cells, and it results in increases in LV wall thickness, LV mass, cardiac output, and diastolic dysfunction (27) . In increased CVD events and death (31, 32) . In addition, asthmatic patients were found to be more physically inactive, obese, and hypertensive (33) , as well as more predisposed to diabetes, chronic obstructive pulmonary disease, and arthritis (34), compared with the norm, and these risk factors could also affect LV hypertrophy.
Intriguingly, we found significant interactions between asthma and SBP on increased LV mass and LVMI-the associations were stronger among participants with pre-hypertension and hypertension.
Although the precise mechanisms remain unclear, Adjusted means and 95% confidence intervals of heart subclinical biomarkers were calculated using mixed regression models. Models controlled for age, sex (male or female), race (black or white), smoking status (current smokers or noncurrent smokers), as fixed effects, antihypertensive medication (yes, no, or missing, with "no" as reference), heart rate (beats/min), high-sensitivity C-reactive protein (mg/l), as well as participants' study identity (ID) numbers as random effects. b is the regression coefficient of asthma in stratified systolic blood pressure (SBP) level or smoking status groups, followed by its p values for statistical significance. The p value for interaction term is given by including the interaction term in the mixed model. TRANSLATIONAL OUTLOOK: A history of asthma from childhood is associated with higher LVMI, especially among patients with pre-hypertension and hypertension.
